Mr. Shkreli went to Washington Thursday morning to testify at the House Oversight and Government Reform Committee hearing on drug pricing. But former Turing Pharmaceuticals and KaloBios CEO Martin Shkreli invoked his Fifth Amendment right not to incriminate himself.
Shkreli may not have spoken much, but, as they say, a picture tells 1,000 words.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Did he seem uncomfortable during his swearing-in?
Or was the notorious pharma dudebro, Wu-Tang Clan fan and future movie subject trying to project the confidence that so often has veered into arrogance since he became the poster child for runaway price hikes last year?
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Maybe he was just checking out the grandeur of the surroundings?
Or listening intently to the questioning?
He did actually speak, though not much on substance.
That’s attorney Benjamin Brafman whispering instructions to his client.
One who did answer questions was current Turing Chief Commercial Officer Nancy Retzlaff. To the left is Howard Schiller, interim CEO of Valeant Pharmaceuticals, another drug company under fire for its aggressive pricing.
Afterwards, Shkreli ran out and tried to get into the wrong car.
Photos: Mark Wilson/Getty Images
